JP2020526483A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526483A5
JP2020526483A5 JP2019570045A JP2019570045A JP2020526483A5 JP 2020526483 A5 JP2020526483 A5 JP 2020526483A5 JP 2019570045 A JP2019570045 A JP 2019570045A JP 2019570045 A JP2019570045 A JP 2019570045A JP 2020526483 A5 JP2020526483 A5 JP 2020526483A5
Authority
JP
Japan
Prior art keywords
subject
csa
period
dose
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526483A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/040181 external-priority patent/WO2019006235A1/en
Publication of JP2020526483A publication Critical patent/JP2020526483A/ja
Publication of JP2020526483A5 publication Critical patent/JP2020526483A5/ja
Priority to JP2023040600A priority Critical patent/JP2023088944A/ja
Priority to JP2025121073A priority patent/JP2025165979A/ja
Pending legal-status Critical Current

Links

JP2019570045A 2017-06-30 2018-06-29 心筋節活性化剤で心不全を治療する方法 Pending JP2020526483A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023040600A JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法
JP2025121073A JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
US62/527,983 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023040600A Division JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法

Publications (2)

Publication Number Publication Date
JP2020526483A JP2020526483A (ja) 2020-08-31
JP2020526483A5 true JP2020526483A5 (https=) 2021-08-05

Family

ID=63013097

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019570045A Pending JP2020526483A (ja) 2017-06-30 2018-06-29 心筋節活性化剤で心不全を治療する方法
JP2023040600A Pending JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法
JP2025121073A Pending JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023040600A Pending JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法
JP2025121073A Pending JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Country Status (22)

Country Link
US (4) US11576910B2 (https=)
EP (2) EP3645002B1 (https=)
JP (3) JP2020526483A (https=)
CN (1) CN110996953A (https=)
AU (2) AU2018290983B2 (https=)
BR (1) BR112019028046A2 (https=)
CA (1) CA3068588A1 (https=)
DK (1) DK3645002T3 (https=)
ES (1) ES3008457T3 (https=)
FI (1) FI3645002T3 (https=)
HR (1) HRP20241729T1 (https=)
HU (1) HUE069805T2 (https=)
LT (1) LT3645002T (https=)
MA (1) MA49508B1 (https=)
MD (1) MD3645002T2 (https=)
MX (2) MX2020000190A (https=)
PL (1) PL3645002T3 (https=)
PT (1) PT3645002T (https=)
RS (1) RS66581B1 (https=)
SI (1) SI3645002T1 (https=)
SM (1) SMT202500067T1 (https=)
WO (1) WO2019006235A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
DK3645002T3 (da) * 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
KR20220009440A (ko) * 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료
US20230090391A1 (en) * 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
WO2021257456A1 (en) * 2020-06-15 2021-12-23 MyoKardia, Inc. Treatment of atrial dysfunction
DK4243825T3 (da) * 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス, インコーポレイテッド 1,4-ジヒドロキナゾリノン化合物およびその使用
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
AU2003279842A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US20080031957A1 (en) 2006-05-15 2008-02-07 Deluca Hector F Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
US9895308B2 (en) * 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
CA3052625A1 (en) 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
DK3645002T3 (da) 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
EP3820851A1 (en) 2018-07-12 2021-05-19 Assia Chemical Industries Ltd Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
FI3599243T3 (fi) 2018-07-26 2023-06-22 Cvie Therapeutics Ltd 17beeta-heterosyklyylidigitaliksen kaltaisia yhdisteitä sydämen vajaatoiminnan hoitoon
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
MX2021010483A (es) 2019-03-05 2021-10-01 Windtree Therapeutics Inc Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf).
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
EP4054588A4 (en) 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
US20230090391A1 (en) 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
DK4243825T3 (da) 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Similar Documents

Publication Publication Date Title
JP2020526483A5 (https=)
JP2023088944A5 (https=)
FI3645002T3 (fi) Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla
JP2020529996A5 (https=)
JP6309454B2 (ja) 癌の併用処置
JP2021533787A5 (https=)
EA020193B1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
JP2015057436A5 (https=)
JP2020502261A5 (https=)
JP2017513809A5 (https=)
JP2021526138A5 (https=)
Patel et al. Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations.
WO2024081611A1 (en) Methods for treating heart failure by administering cardiac sarcomere activators
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
CN117529320A (zh) 用于治疗病毒感染的rock2抑制剂
JP2019519544A5 (https=)
EP2303259A1 (en) Dronedarone for the prevention of cardioversion
WO2014176543A2 (en) Methods of self-administration of vanoxerine for terminating acute episodes of cardiac arrhythmia in mammals
WO2014134419A1 (en) Use of ikach blockers for the treatment of cardiac diseases
JP2023531930A5 (https=)
MX2022006404A (es) Composicion farmaceutica para el tratamiento de la enfermedad vascular pulmonar y/o disfuncion cardiaca en pacientes paliados con fontan.
CN116157119A (zh) 一种ARNi与钙离子拮抗剂的药物组合物与应用
JP2021091608A5 (https=)
JP6028983B2 (ja) ビダラビンによる心房細動治療
US20230201313A1 (en) Methods of treating left ventricle hypertrophy